Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cytokinetics, Incorporated

CYTK ✗ NOT COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$73.77

▲ +0.20%

Market Cap $10.26B · Vol 624.33K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$10.26B

Large Cap

Div Yield

N/A

EPS Growth

+6.44%

YoY

RSI (14)

42.10

Momentum

Beta

0.39

vs Market

52W High

$88.00

16.17% below

52W Low

$47.24

56.16% above

Volume

624.33K

Avg 626.40K

P/B

N/A

Price-to-book

ROE

197.47%

Return on equity

Free Float

97.28%

Public shares

Shariah Compliance8 STANDARDS

✗ Cytokinetics, Incorporated (CYTK) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CYTK pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.24%

-3.51%

+6.50%

+15.94%

YTD

+16.10%

+38.35%

+110.47%

+149.90%

Financials & Valuation

TTM · Annual

Total Revenue	$88.04M
Net Income	$-784,955,000.00
Revenue Growth (YoY)	-57.13%
Gross Margin	100.00%
Operating Margin	-695.44%
Net Profit Margin	-891.60%
ROE	197.47%
ROA · ROIC	-55.55% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	86.68
P/B	N/A
P/FCF	N/A
EPS Growth	+6.44%
Outstanding Shares	139.02M

Technical Indicators

50-Day SMA	$78.33
200-Day SMA	$69.95
RSI (14)	42.10
Beta	0.39
52-Week High	$88.00
52-Week Low	$47.24

Volume Today	624.33K
Avg Daily Volume (30D)	626.40K
Relative Volume	1.00x
Volatility (10D)	46.69
Volatility (30D)	39.77
Free Float	97.28%

Analyst Consensus

BUY

Current Price $73.77

Mean Target $110.26

52W Low$47.24 52W High$88.00

Current

Target

$47.24 $88.00

Current Analyst target

+49.46% upside potential · 22 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SGMVF2

ISINUS23282W6057

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -1.15% ARGX.BR argenx SE -0.23% ARGX argenx SE +0.04% INSM Insmed Incorporated +1.67% 2269.HK WuXi Biologics (Cayman) Inc. -1.05%

Company Profile

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.